Update in NIRAF and NIRF Inflammation Imaging

Sunday, March 9, 2025

9:35 AM – 9:43 AM ET

Speaker(s)

Farouc A. Jaffer, MD, PhD

Director Coronary Intervention and CTO PCI Program
Massachusetts General Hospital / Harvard Medical School
Boston, Massachusetts, United States

Disclosure(s): Intravascular Imaging, Durvena, Fastwave: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Massachusetts General Hospital: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Royalty - Canon, Terumo, Spectrawave from IP held by MGH (Ongoing); Shockwave, Novartis, Magenta Medical, Medtronic, Cleerly, Genomadix: Consulting Fees (e.g., advisory boards) (Ongoing); Siemens, Canon, Neovasc/Shockwave, Teleflex, Boston Scientific, Amarin, Heartflow, OrbusNeich: Grant/Research Support (Ongoing)

Disclosure(s):

Farouc A. Jaffer, MD, PhD: Intravascular Imaging, Durvena, Fastwave: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Massachusetts General Hospital: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Royalty - Canon, Terumo, Spectrawave from IP held by MGH (Ongoing); Shockwave, Novartis, Magenta Medical, Medtronic, Cleerly, Genomadix: Consulting Fees (e.g., advisory boards) (Ongoing); Siemens, Canon, Neovasc/Shockwave, Teleflex, Boston Scientific, Amarin, Heartflow, OrbusNeich: Grant/Research Support (Ongoing)